Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03-30

AUTHORS

Makoto Shiragami, Akiko Mizukami, Toshihiko Kaise, Desmond Curran, Desiree Van Oorschot, Benjamin Bracke, Daisuke Watanabe

ABSTRACT

INTRODUCTION: The incidence of herpes zoster (HZ) rises steeply after the age of 50 years and the number of HZ cases and complications such as postherpetic neuralgia (PHN) is predicted to increase because of the ageing population. The objective of this study was to estimate the cost-effectiveness of recombinant zoster vaccine (RZV) compared with no vaccine for the Japanese population aged ≥ 65 years. METHODS: A multi-cohort static Markov model with a cycle length of 1 year was used to follow a hypothetical cohort of 1 million people aged ≥ 65 years over their remaining lifetime. Vaccination at ≥ 65 years was used in alignment with the influenza and pneumococcal vaccines recommended from 65 years. Japan-specific data inputs for the model were obtained from local data sources. Age-stratified vaccine efficacy and waning rates were based on published clinical trial data. In the base-case analysis, vaccine coverage was assumed to be 40% with a second dose compliance of 95%. Costs and outcomes were discounted at 2% annually and the incremental cost-effectiveness ratio (ICER) was calculated from both a payer's and the societal perspective. Sensitivity analyses were carried out to explore the overall uncertainty in the model. RESULTS: Vaccination with RZV was projected to prevent 48,943 HZ cases and 12,136 PHN cases per million people aged ≥ 65 years compared with no vaccination. The incremental costs and quality-adjusted life years (QALYs) gained were ¥9.99 billion and 2314 QALYs from a payer's perspective and ¥9.34 billion and 2314 QALYs from a societal perspective. The resulting ICERs were approximately ¥4,320,000 and ¥4,040,000 per QALY gained from a payer's and the societal perspective, respectively. The ICER remained below a willingness-to-pay threshold of ¥5,000,000 for most sensitivity analyses carried out. CONCLUSION: Vaccination against HZ with RZV would be cost-effective compared with no vaccination for the Japanese population aged ≥ 65 years. TRIAL REGISTRATION: GSK study identifier: HO-16-17837. FUNDING: GlaxoSmithKline Biologicals SA. More... »

PAGES

1-17

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13555-019-0291-4

DOI

http://dx.doi.org/10.1007/s13555-019-0291-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113144353

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30929219


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Teikyo Heisei University", 
          "id": "https://www.grid.ac/institutes/grid.440938.2", 
          "name": [
            "Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shiragami", 
        "givenName": "Makoto", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.488295.a", 
          "name": [
            "Healthoutcomes Department, GSK, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mizukami", 
        "givenName": "Akiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.488295.a", 
          "name": [
            "Healthoutcomes Department, GSK, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaise", 
        "givenName": "Toshihiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Belgium)", 
          "id": "https://www.grid.ac/institutes/grid.425090.a", 
          "name": [
            "Value Evidence Department, GSK, Wavre, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Curran", 
        "givenName": "Desmond", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Belgium)", 
          "id": "https://www.grid.ac/institutes/grid.425090.a", 
          "name": [
            "Value Evidence Department, GSK, Wavre, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Oorschot", 
        "givenName": "Desiree", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Belgium)", 
          "id": "https://www.grid.ac/institutes/grid.425090.a", 
          "name": [
            "Value Evidence Department, GSK, Wavre, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bracke", 
        "givenName": "Benjamin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aichi Medical University", 
          "id": "https://www.grid.ac/institutes/grid.411234.1", 
          "name": [
            "Department of Dermatology, Aichi Medical University, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Watanabe", 
        "givenName": "Daisuke", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1471-2334-14-402", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000552443", 
          "https://doi.org/10.1186/1471-2334-14-402"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.vaccine.2008.12.024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000584253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1386-6532(10)70002-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008033904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jmv.21599", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015253824"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jmv.21599", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015253824"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/hv.28670", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016381549"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4065/mcp.2010.0618", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016859358"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.12379", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020354496"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2188/jea.je20140210", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025161502"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.vaccine.2014.01.058", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026925501"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/14651858.cd006866.pub3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026999454"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12879-017-2185-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034723545", 
          "https://doi.org/10.1186/s12879-017-2185-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12879-017-2185-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034723545", 
          "https://doi.org/10.1186/s12879-017-2185-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrdp.2015.16", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037084323", 
          "https://doi.org/10.1038/nrdp.2015.16"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2016.08.726", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044255756"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4091/iken.16.157", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044291718"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4091/iken.16.157", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044291718"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.vaccine.2015.09.073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044482694"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmjopen-2014-004833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045008515"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1603800", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047387134"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1501184", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048462622"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/hec.1481", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051425753"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/hec.1481", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051425753"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/1346-8138.13639", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053526031"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/2051013615599151", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064085037"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/2051013615599151", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064085037"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/m15-0093", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073742604"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12877-017-0420-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074211022", 
          "https://doi.org/10.1186/s12877-017-0420-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12877-017-0420-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074211022", 
          "https://doi.org/10.1186/s12877-017-0420-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/1346-8138.13784", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084208157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.vaccine.2017.04.046", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085162264"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.vaccine.2017.04.046", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085162264"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/21645515.2017.1345399", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090694032"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0181565", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090916841"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40801-017-0119-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092125743", 
          "https://doi.org/10.1007/s40801-017-0119-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40261-017-0581-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092445446", 
          "https://doi.org/10.1007/s40261-017-0581-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/21645515.2018.1442162", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101132006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13555-018-0236-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103520532", 
          "https://doi.org/10.1007/s13555-018-0236-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13555-018-0236-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103520532", 
          "https://doi.org/10.1007/s13555-018-0236-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13555-018-0236-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103520532", 
          "https://doi.org/10.1007/s13555-018-0236-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.vaccine.2018.07.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105564262"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/21645515.2018.1509645", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106275817"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/21645515.2018.1509645", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106275817"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03-30", 
    "datePublishedReg": "2019-03-30", 
    "description": "INTRODUCTION: The incidence of herpes zoster (HZ) rises steeply after the age of 50\u00a0years and the number of HZ cases and complications such as postherpetic neuralgia (PHN) is predicted to increase because of the ageing population. The objective of this study was to estimate the cost-effectiveness of recombinant zoster vaccine (RZV) compared with no vaccine for the Japanese population aged \u2265 65\u00a0years.\nMETHODS: A multi-cohort static Markov model with a cycle length of 1\u00a0year was used to follow a hypothetical cohort of 1 million people aged \u2265 65\u00a0years over their remaining lifetime. Vaccination at \u2265 65\u00a0years was used in alignment with the influenza and pneumococcal vaccines recommended from 65\u00a0years. Japan-specific data inputs for the model were obtained from local data sources. Age-stratified vaccine efficacy and waning rates were based on published clinical trial data. In the base-case analysis, vaccine coverage was assumed to be 40% with a second dose compliance of 95%. Costs and outcomes were discounted at 2% annually and the incremental cost-effectiveness ratio (ICER) was calculated from both a payer's and the societal perspective. Sensitivity analyses were carried out to explore the overall uncertainty in the model.\nRESULTS: Vaccination with RZV was projected to prevent 48,943 HZ cases and 12,136 PHN cases per million people aged \u2265 65\u00a0years compared with no vaccination. The incremental costs and quality-adjusted life years (QALYs) gained were \u00a59.99 billion and 2314 QALYs from a payer's perspective and \u00a59.34 billion and 2314 QALYs from a societal perspective. The resulting ICERs were approximately \u00a54,320,000 and \u00a54,040,000 per QALY gained from a payer's and the societal perspective, respectively. The ICER remained below a willingness-to-pay threshold of \u00a55,000,000 for most sensitivity analyses carried out.\nCONCLUSION: Vaccination against HZ with RZV would be cost-effective compared with no vaccination for the Japanese population aged \u2265 65\u00a0years.\nTRIAL REGISTRATION: GSK study identifier: HO-16-17837.\nFUNDING: GlaxoSmithKline Biologicals SA.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s13555-019-0291-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1047318", 
        "issn": [
          "2193-8210", 
          "2190-9172"
        ], 
        "name": "Dermatology and Therapy", 
        "type": "Periodical"
      }
    ], 
    "name": "Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older", 
    "pagination": "1-17", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "fdc72a3afd85ce958132f17318c3dfd9131ba3127dac43cfbd378f6970e2ecc4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30929219"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101590450"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13555-019-0291-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113144353"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13555-019-0291-4", 
      "https://app.dimensions.ai/details/publication/pub.1113144353"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000370_0000000370/records_46738_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs13555-019-0291-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13555-019-0291-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13555-019-0291-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13555-019-0291-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13555-019-0291-4'


 

This table displays all metadata directly associated to this object as RDF triples.

213 TRIPLES      21 PREDICATES      59 URIs      18 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13555-019-0291-4 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N92507cbafc314400be59ffeef93e6558
4 schema:citation sg:pub.10.1007/s13555-018-0236-3
5 sg:pub.10.1007/s40261-017-0581-5
6 sg:pub.10.1007/s40801-017-0119-4
7 sg:pub.10.1038/nrdp.2015.16
8 sg:pub.10.1186/1471-2334-14-402
9 sg:pub.10.1186/s12877-017-0420-9
10 sg:pub.10.1186/s12879-017-2185-3
11 https://doi.org/10.1002/14651858.cd006866.pub3
12 https://doi.org/10.1002/hec.1481
13 https://doi.org/10.1002/jmv.21599
14 https://doi.org/10.1016/j.jval.2016.08.726
15 https://doi.org/10.1016/j.vaccine.2008.12.024
16 https://doi.org/10.1016/j.vaccine.2014.01.058
17 https://doi.org/10.1016/j.vaccine.2015.09.073
18 https://doi.org/10.1016/j.vaccine.2017.04.046
19 https://doi.org/10.1016/j.vaccine.2018.07.005
20 https://doi.org/10.1016/s1386-6532(10)70002-0
21 https://doi.org/10.1056/nejmoa1501184
22 https://doi.org/10.1056/nejmoa1603800
23 https://doi.org/10.1080/21645515.2017.1345399
24 https://doi.org/10.1080/21645515.2018.1442162
25 https://doi.org/10.1080/21645515.2018.1509645
26 https://doi.org/10.1111/1346-8138.13639
27 https://doi.org/10.1111/1346-8138.13784
28 https://doi.org/10.1111/jdv.12379
29 https://doi.org/10.1136/bmjopen-2014-004833
30 https://doi.org/10.1177/2051013615599151
31 https://doi.org/10.1371/journal.pone.0181565
32 https://doi.org/10.2188/jea.je20140210
33 https://doi.org/10.4065/mcp.2010.0618
34 https://doi.org/10.4091/iken.16.157
35 https://doi.org/10.4161/hv.28670
36 https://doi.org/10.7326/m15-0093
37 schema:datePublished 2019-03-30
38 schema:datePublishedReg 2019-03-30
39 schema:description INTRODUCTION: The incidence of herpes zoster (HZ) rises steeply after the age of 50 years and the number of HZ cases and complications such as postherpetic neuralgia (PHN) is predicted to increase because of the ageing population. The objective of this study was to estimate the cost-effectiveness of recombinant zoster vaccine (RZV) compared with no vaccine for the Japanese population aged ≥ 65 years. METHODS: A multi-cohort static Markov model with a cycle length of 1 year was used to follow a hypothetical cohort of 1 million people aged ≥ 65 years over their remaining lifetime. Vaccination at ≥ 65 years was used in alignment with the influenza and pneumococcal vaccines recommended from 65 years. Japan-specific data inputs for the model were obtained from local data sources. Age-stratified vaccine efficacy and waning rates were based on published clinical trial data. In the base-case analysis, vaccine coverage was assumed to be 40% with a second dose compliance of 95%. Costs and outcomes were discounted at 2% annually and the incremental cost-effectiveness ratio (ICER) was calculated from both a payer's and the societal perspective. Sensitivity analyses were carried out to explore the overall uncertainty in the model. RESULTS: Vaccination with RZV was projected to prevent 48,943 HZ cases and 12,136 PHN cases per million people aged ≥ 65 years compared with no vaccination. The incremental costs and quality-adjusted life years (QALYs) gained were ¥9.99 billion and 2314 QALYs from a payer's perspective and ¥9.34 billion and 2314 QALYs from a societal perspective. The resulting ICERs were approximately ¥4,320,000 and ¥4,040,000 per QALY gained from a payer's and the societal perspective, respectively. The ICER remained below a willingness-to-pay threshold of ¥5,000,000 for most sensitivity analyses carried out. CONCLUSION: Vaccination against HZ with RZV would be cost-effective compared with no vaccination for the Japanese population aged ≥ 65 years. TRIAL REGISTRATION: GSK study identifier: HO-16-17837. FUNDING: GlaxoSmithKline Biologicals SA.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree false
43 schema:isPartOf sg:journal.1047318
44 schema:name Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older
45 schema:pagination 1-17
46 schema:productId N26c2544a8d434ec0b2a5fe2709e0c5c4
47 N8dadff20865f41a8974aea5838d3c48d
48 N90cd3348059344bda97bbbef3a296d1d
49 Nbf5b91aa50df43d0bc83a65b1ef6a431
50 Nc6210ef0d1d64ffeb414a48df3bae550
51 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113144353
52 https://doi.org/10.1007/s13555-019-0291-4
53 schema:sdDatePublished 2019-04-11T13:27
54 schema:sdLicense https://scigraph.springernature.com/explorer/license/
55 schema:sdPublisher N8afa5d7099d9422b9bea9db3da2a2f3a
56 schema:url https://link.springer.com/10.1007%2Fs13555-019-0291-4
57 sgo:license sg:explorer/license/
58 sgo:sdDataset articles
59 rdf:type schema:ScholarlyArticle
60 N0c575360706a44aa8a5fe2c0424fe6f7 schema:affiliation https://www.grid.ac/institutes/grid.488295.a
61 schema:familyName Kaise
62 schema:givenName Toshihiko
63 rdf:type schema:Person
64 N24e3c82ae4ae4d238602c3a379211c12 schema:affiliation https://www.grid.ac/institutes/grid.488295.a
65 schema:familyName Mizukami
66 schema:givenName Akiko
67 rdf:type schema:Person
68 N26c2544a8d434ec0b2a5fe2709e0c5c4 schema:name doi
69 schema:value 10.1007/s13555-019-0291-4
70 rdf:type schema:PropertyValue
71 N41ac07e692b24ad38dd68024ac1fc622 rdf:first Na4dc831822be456dbd489a92164b8539
72 rdf:rest rdf:nil
73 N565c64196dac479793422514afdd3e37 rdf:first N9c70522c08f94e38a6b306c63733d15a
74 rdf:rest N857d1db6b24f4e4f9c8c717ef7fed47d
75 N5cea51807864406da96fa9085fa4062f rdf:first N24e3c82ae4ae4d238602c3a379211c12
76 rdf:rest N9d1360d7df5944cdbdbeec860d9f5e0f
77 N62959dcca88f4634a010967dc52c1415 schema:affiliation https://www.grid.ac/institutes/grid.440938.2
78 schema:familyName Shiragami
79 schema:givenName Makoto
80 rdf:type schema:Person
81 N7ce0e8edc833422c878da5c1672d64e4 rdf:first N80c2974744874e0189ee952e0bec9674
82 rdf:rest N41ac07e692b24ad38dd68024ac1fc622
83 N80c2974744874e0189ee952e0bec9674 schema:affiliation https://www.grid.ac/institutes/grid.425090.a
84 schema:familyName Bracke
85 schema:givenName Benjamin
86 rdf:type schema:Person
87 N857d1db6b24f4e4f9c8c717ef7fed47d rdf:first Nbc4b83df58a84a629acaf6986f45a900
88 rdf:rest N7ce0e8edc833422c878da5c1672d64e4
89 N8afa5d7099d9422b9bea9db3da2a2f3a schema:name Springer Nature - SN SciGraph project
90 rdf:type schema:Organization
91 N8dadff20865f41a8974aea5838d3c48d schema:name nlm_unique_id
92 schema:value 101590450
93 rdf:type schema:PropertyValue
94 N90cd3348059344bda97bbbef3a296d1d schema:name dimensions_id
95 schema:value pub.1113144353
96 rdf:type schema:PropertyValue
97 N92507cbafc314400be59ffeef93e6558 rdf:first N62959dcca88f4634a010967dc52c1415
98 rdf:rest N5cea51807864406da96fa9085fa4062f
99 N9c70522c08f94e38a6b306c63733d15a schema:affiliation https://www.grid.ac/institutes/grid.425090.a
100 schema:familyName Curran
101 schema:givenName Desmond
102 rdf:type schema:Person
103 N9d1360d7df5944cdbdbeec860d9f5e0f rdf:first N0c575360706a44aa8a5fe2c0424fe6f7
104 rdf:rest N565c64196dac479793422514afdd3e37
105 Na4dc831822be456dbd489a92164b8539 schema:affiliation https://www.grid.ac/institutes/grid.411234.1
106 schema:familyName Watanabe
107 schema:givenName Daisuke
108 rdf:type schema:Person
109 Nbc4b83df58a84a629acaf6986f45a900 schema:affiliation https://www.grid.ac/institutes/grid.425090.a
110 schema:familyName Van Oorschot
111 schema:givenName Desiree
112 rdf:type schema:Person
113 Nbf5b91aa50df43d0bc83a65b1ef6a431 schema:name pubmed_id
114 schema:value 30929219
115 rdf:type schema:PropertyValue
116 Nc6210ef0d1d64ffeb414a48df3bae550 schema:name readcube_id
117 schema:value fdc72a3afd85ce958132f17318c3dfd9131ba3127dac43cfbd378f6970e2ecc4
118 rdf:type schema:PropertyValue
119 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
120 schema:name Medical and Health Sciences
121 rdf:type schema:DefinedTerm
122 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
123 schema:name Public Health and Health Services
124 rdf:type schema:DefinedTerm
125 sg:journal.1047318 schema:issn 2190-9172
126 2193-8210
127 schema:name Dermatology and Therapy
128 rdf:type schema:Periodical
129 sg:pub.10.1007/s13555-018-0236-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103520532
130 https://doi.org/10.1007/s13555-018-0236-3
131 rdf:type schema:CreativeWork
132 sg:pub.10.1007/s40261-017-0581-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092445446
133 https://doi.org/10.1007/s40261-017-0581-5
134 rdf:type schema:CreativeWork
135 sg:pub.10.1007/s40801-017-0119-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092125743
136 https://doi.org/10.1007/s40801-017-0119-4
137 rdf:type schema:CreativeWork
138 sg:pub.10.1038/nrdp.2015.16 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037084323
139 https://doi.org/10.1038/nrdp.2015.16
140 rdf:type schema:CreativeWork
141 sg:pub.10.1186/1471-2334-14-402 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000552443
142 https://doi.org/10.1186/1471-2334-14-402
143 rdf:type schema:CreativeWork
144 sg:pub.10.1186/s12877-017-0420-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074211022
145 https://doi.org/10.1186/s12877-017-0420-9
146 rdf:type schema:CreativeWork
147 sg:pub.10.1186/s12879-017-2185-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034723545
148 https://doi.org/10.1186/s12879-017-2185-3
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1002/14651858.cd006866.pub3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026999454
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1002/hec.1481 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051425753
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1002/jmv.21599 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015253824
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1016/j.jval.2016.08.726 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044255756
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1016/j.vaccine.2008.12.024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000584253
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1016/j.vaccine.2014.01.058 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026925501
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1016/j.vaccine.2015.09.073 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044482694
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1016/j.vaccine.2017.04.046 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085162264
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1016/j.vaccine.2018.07.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105564262
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1016/s1386-6532(10)70002-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008033904
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1056/nejmoa1501184 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048462622
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1056/nejmoa1603800 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047387134
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1080/21645515.2017.1345399 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090694032
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1080/21645515.2018.1442162 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101132006
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1080/21645515.2018.1509645 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106275817
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1111/1346-8138.13639 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053526031
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1111/1346-8138.13784 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084208157
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1111/jdv.12379 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020354496
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1136/bmjopen-2014-004833 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045008515
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1177/2051013615599151 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064085037
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1371/journal.pone.0181565 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090916841
191 rdf:type schema:CreativeWork
192 https://doi.org/10.2188/jea.je20140210 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025161502
193 rdf:type schema:CreativeWork
194 https://doi.org/10.4065/mcp.2010.0618 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016859358
195 rdf:type schema:CreativeWork
196 https://doi.org/10.4091/iken.16.157 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044291718
197 rdf:type schema:CreativeWork
198 https://doi.org/10.4161/hv.28670 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016381549
199 rdf:type schema:CreativeWork
200 https://doi.org/10.7326/m15-0093 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073742604
201 rdf:type schema:CreativeWork
202 https://www.grid.ac/institutes/grid.411234.1 schema:alternateName Aichi Medical University
203 schema:name Department of Dermatology, Aichi Medical University, Aichi, Japan
204 rdf:type schema:Organization
205 https://www.grid.ac/institutes/grid.425090.a schema:alternateName GlaxoSmithKline (Belgium)
206 schema:name Value Evidence Department, GSK, Wavre, Belgium
207 rdf:type schema:Organization
208 https://www.grid.ac/institutes/grid.440938.2 schema:alternateName Teikyo Heisei University
209 schema:name Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo, Japan
210 rdf:type schema:Organization
211 https://www.grid.ac/institutes/grid.488295.a schema:alternateName GlaxoSmithKline (Japan)
212 schema:name Healthoutcomes Department, GSK, Tokyo, Japan
213 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...